Boron-based drugs have attracted broad interest from both academia and industry. This book describes advanced boron-based drugs, new applications and related pharmacology. Authoritative yet accessible, it begins with an introduction to general boron chemistry, before detailing FDA-approved boron-containing drugs, boron agents for neutron capture therapy and clinical reports for boron neutron capture therapy. Designed for academic and industrial scientists, this is a valuable resource that brings together in one comprehensive volume cutting-edge information on the current state of boron-based medicinal chemistry.

Fundamentals and Applications of Boron Chemistry highlights its impressive potential for current and future developments across a range of fields, providing foundational information on boron chemistry and systematically summarizing applications of boron in energy, medicinal chemistry, and materials chemistry. Beginning with an introduction to boron chemistry which outlines the boron element and its physical and chemical properties, this book goes on to discuss advances in boron coordination chemistry, before delving deeper into key fields of application. The latest developments in boron-based catalysts in organic reactions are reviewed, followed by novel emerging boron-containing materials and their potential applications in areas such as hydrogen storage, and boron materials with special optical activity. Finally, advance boron-based drugs and therapies are explored. This book fills the current market gap, systematically summarizing developments and applications of boron in energy, medicinal chemistry, and materials chemistry in a single, accessible volume. It is a valuable reference for chemists, students, and researchers in relative areas.

The book focuses on two concurrent experimental therapies in cancer treatment known as boron neutron capture therapy (BNCT) and gadolinium neutron capture therapy (GdNCT) using a variety of boron- and gadolinium-based compounds. Some of the gadolinium compounds serve the dual purpose as being MRI contrast agents and GdNCT agents. The book describes why BNCT & GdNCT were not at the forefront of the clinical trials during the past seven to eight decades since the discovery of neutrons by John Chadwick in 1932 and how the latest development in the synthesis of target boron- and gadolinium-based drugs have turned the area to be the hottest one and worthy of further investigation with the new clinical trials in the USA and elsewhere.